Carbon Biosciences
AAV capsid discovery and gene therapy manufacturing platform
- Sector
- Biotech
- Headquarters
- BOSTON, MA
- Founded
- 2021
- Latest Form D
- $38M, Jan 2022
- Total capital
- $38M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $38M
- 1 Form D · last Jan 2022
- 57 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 15 pending · first 2025
- Rank in peer group#73 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$38M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#73 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Robert KotinResearcherExecutive Officer, DirectorLinked by 1 patent
- Chen SchorDirectorNamed in SEC Form D filings
- David SteinbergDirectorNamed in SEC Form D filings
- Derek YoonDirectorNamed in SEC Form D filings
- Geeta VemuriDirectorNamed in SEC Form D filings
- Jacopo LeonardiExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- John LawrenceExecutive OfficerNamed in SEC Form D filings
- Robert HadfieldExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 16- GrantedProtoparvovirus Compositions Comprising A Protoparvovirus Variant VP1 Capsid Polypeptide And Related MethodsUSPTOUS 12,383,615
- PendingParvovirus Compositions And Related Methods For Gene TherapyUSPTOApplication PCTUS2025047412
- PendingParvovirus Compositions And Related Methods For Gene TherapyUSPTOApplication PCTUS2025047405
Show all 16 patent records
- Protoparvovirus Compositions Comprising A Protoparvovirus Variant VP1 Capsid Polypeptide And Related MethodsAug 12, 2025 · US 12,383,615Granted
- Parvovirus Compositions And Related Methods For Gene TherapyApplication PCTUS2025047412Pending
- Parvovirus Compositions And Related Methods For Gene TherapyApplication PCTUS2025047405Pending
- Parvovirus Compositions And Related Methods For Gene TherapyApplication 19167419Pending
- Parvovirus Compositions And Methods For Gene TherapyApplication 63698907Pending
- Parvovirus Compositions And Related Methods For Gene TherapyApplication 63697724Pending
- Parvovirus Compositions And Related Methods For Gene TherapyApplication 63697735Pending
- Protoparvovirus Compositions Comprising A Protoparvovirus Variant VP1 Capsid Polypeptide And Related MethodsApplication PCTUS2024021126Pending
- Parvovirus Compositions And Related Methods For Gene TherapyApplication PCTUS2024020608Pending
- Parvovirus Compositions And Related Methods For Gene TherapyApplication 63624635Pending
- Parvovirus Compositions And Related Methods For Gene TherapyApplication 63618170Pending
- Protoparvovirus Compositions Comprising A Protoparvovirus Variant VP1 Capsid Polypeptide And Related MethodsApplication 63545449Pending
- Parvovirus Compositions And Related Methods For Gene TherapyApplication 63545403Pending
- Protoparvovirus Compositions Comprising A Protoparvovirus Variant VP1 Capsid Polypeptide And Related MethodsApplication 63454259Pending
- Parvovirus Compositions And Methods For Gene TherapyApplication PCTUS2025047787Pending
- Parvovirus Compositions And Related Methods For Gene TherapyApplication 63454258Pending
Related companies, and why
- Arrakis TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Abeona Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- Prevail TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Hoth Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Cristcot LLCSimilar federal contract value in Biotech · null in contracts
- Angiex, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .